Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy

BACKGROUND: Dose escalation is often recommended for loss of response in anti-TNFα-treated patients with Crohn's disease (CD). This 52-week phase 3, multicenter study investigated the efficacy and safety of escalation to adalimumab 80 mg every other week (EOW) in Japanese patients with CD who l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Inflamm Intest Dis
Main Authors: Motoya, Satoshi, Watanabe, Mamoru, Wallace, Kori, Lazar, Andreas, Nishimura, Yasuko, Ozawa, Morio, Thakkar, Roopal, Robinson, Anne M., Singh, Ravi Shankar Prasad, Mostafa, Nael M., Suzuki, Yasuo, Hibi, Toshifumi
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2018
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135232/
https://ncbi.nlm.nih.gov/pubmed/30221150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000486786
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados